Triple-Negative Breast Cancer

Winkeljohn, Debra

doi:10.1188/08.cjon.861-863

Cited by 4 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several immunohistochemical and pathological features of breast cancer subgroups are summarized and compared in Table 1, based on references [13, 14]. TNBC are characterized by a number of clinical and histological features [15–19]. The TNBC-subgroups share the following features: a) TNBC is more prevalent among young African, African-American [17, 18] and Latino women [17, 19], accounting for approximately 25% of all breast cancer patients originating from these ethic groups.…”

Section: Pathological Features Of Triple Negative and Basal-like Bmentioning

confidence: 99%

“…TNBC are characterized by a number of clinical and histological features [15–19]. The TNBC-subgroups share the following features: a) TNBC is more prevalent among young African, African-American [17, 18] and Latino women [17, 19], accounting for approximately 25% of all breast cancer patients originating from these ethic groups. The prevalence of TNBC is also higher among young obese women [19–21]; b) Because of the lack of ER, PR and HER-2, TNBC patients are insensitive to most currently available hormonal or ER-targeted and HER-2-based therapies.…”

Section: Pathological Features Of Triple Negative and Basal-like Bmentioning

confidence: 99%

See 1 more Smart Citation

ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches

Chen

Russo

2009

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

117

104

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is a type of aggressive breast cancer lacking the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2). TNBC patients account for approximately 15% of total breast cancer patients and are more prevalent among young African, African-American and Latino women patients. The currently available ER-targeted and Her-2-based therapies are not effective for treating TNBC. Recent studies have revealed a number of novel features of TNBC. In the present work, we comprehensively addressed these features and discussed potential therapeutic approaches based on these features for TNBC, with particular focus on: 1) the pathological features of TNBC/basal-like breast cancer; 2) E2/ERβ – mediated signaling pathways; 3) G-protein coupling receptor-30/epithelial growth factor receptor (GPCR-30/EGFR) signaling pathway; 4) interactions of ERβ with breast cancer 1/2 (BRCA1/2); 5) chemokine CXCL8 and related chemokines; 6) altered microRNA signatures and suppression of ERα expression/ERα-signaling by micro-RNAs; 7) altered expression of several pro-oncongenic and tumor suppressor proteins; and 8) genotoxic effects caused by oxidative estrogen metabolites. Gaining better insights into these molecular pathways in TNBC may lead to identification of novel biomarkers and targets for development of diagnostic and therapeutic approaches for prevention and treatment of TNBC.

show abstract

Section: Pathological Features Of Triple Negative and Basal-like Bmentioning

confidence: 99%

Section: Pathological Features Of Triple Negative and Basal-like Bmentioning

confidence: 99%

ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches

Chen

Russo

2009

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

117

104

View full text Add to dashboard Cite

show abstract

“…TNBC also has poor prognosis, low survival and high recurrence rates. TNBC treatments usually involve systemic chemotherapy infusions47.…”

Section: Discussionmentioning

confidence: 99%

Theranostic barcoded nanoparticles for personalized cancer medicine

et al. 2016

View full text Add to dashboard Cite

Personalized medicine promises to revolutionize cancer therapy by matching the most effective treatment to the individual patient. Using a nanoparticle-based system, we predict the therapeutic potency of anticancer medicines in a personalized manner. We carry out the diagnostic stage through a multidrug screen performed inside the tumour, extracting drug activity information with single cell sensitivity. By using 100 nm liposomes, loaded with various cancer drugs and corresponding synthetic DNA barcodes, we find a correlation between the cell viability and the drug it was exposed to, according to the matching barcodes. Based on this screen, we devise a treatment protocol for mice bearing triple-negative breast-cancer tumours, and its results confirm the diagnostic prediction. We show that the use of nanotechnology in cancer care is effective for generating personalized treatment protocols.

show abstract

“…The prevalence of TNBC is also higher in case of young obese women [22,24,25] and in patients with metabolic syndrome [26].…”

Section: Patient Ethnicity Of Tnbcmentioning

confidence: 98%

“…TNBC is more prevalent among young African, AfricanAmerican [2,23] and Latino women [2,24], accounting for approximately 25% of all breast cancer patients originating from these ethic groups. The prevalence of TNBC is also higher in case of young obese women [22,24,25] and in patients with metabolic syndrome [26].…”

Section: Patient Ethnicity Of Tnbcmentioning

confidence: 99%